Posted by Michael Wonder on 05 Feb 2025
Medexus and Ontario's Provincial Health Services successfully complete agreements for public reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada
4 February 2025 - Medexus recently completed listing agreements with Ontario's Ministry of Health (Ontario Public Drug Programs) and Ontario Health (Cancer Care Ontario) for Trecondyv (treosulfan for injection).
The Ontario Public Drug Programs will now reimburse eligible claims made for Trecondyv, subject to satisfaction of any relevant conditions set out in the agreements.
